Alimetry is taking the next steps in gastric dysfunction diagnosis and treatment. The company has developed a non-invasive wearable device for real-time gastric mapping, symptom tracking, and analysis, resulting in a rapid and objective diagnostics tool for a variety of gastric intestinal (GI) disorders. This device can greatly reduce the uncertainties and trauma currently associated with a gastric disorder diagnosis.
Based in Auckland, Alimetry is built on a decade of scientific and technological research in the GI field and led by an executive team with internationally respected medical, technological, and med-tech commercialisation experience.
Amaroq Therapeutics, a new biotech start-up spun out of the University of Otago, is one of the world’s most advanced programs in developing next-generation RNA therapy to target cancer.
The Amaroq Therapeutics team, led by Chief Scientific Officer and founder, Dr Sarah Diermeier, are pioneers in exploring the use of lncRNA molecules as therapeutic targets and diagnostic markers in the treatment of cancer. They will be working on therapies to treat common cancers such as breast, colorectal and liver cancer.
The study of long non-coding RNAs (lncRNAs), often referred to as “dark matter” of the genome, are molecules naturally present in cells. They have become one of the hottest areas of research globally as they can act as key cell regulators despite not coding for proteins.
Avalia’s proprietary immune system activating platform generates targeted cellular responses for the prevention and treatment of infectious disease and cancer.
Avalia’s lead program is targeting a cure for the 257 million people living with chronic hepatitis B infection – a liver disease. With no effective cure, chronic hepatitis B can lead to cirrhosis, liver cancer and requirement for liver transplants, and globally still causes 1 million deaths per annum.
Through collaborations, Avalia is developing a pipeline of preventative vaccines for malaria and influenza, and new immune-targeting treatments for cancer.
CAS has developed an innovative and practical software platform to help automate the compliance, consenting, and auditing processes through artificial intelligence. Their business is focusing on the AEC (Architecture, Engineering, and Construction) and BIM (Building Information Modeling) Industries to help streamline the development process from a regulatory, design, engineering, and construction perspective.
A spin-out from the University of Auckland’s School of Computer Science, CAS have developed a strong product offering which has received strong support from central Government, Iwi, and the private sector.
Chitogel is a medical device company with an advanced manufacturing facility based in Lower Hutt. They supply medical kits that optimse the wound healing environment and significantly improve patient outcomes following sinus surgery.
Originating from University of Otago research, Chitogel's developments are backed by over 10 years of research and clinical evidence, including 17 published studies and scientific papers and the observation of successful outcomes of a diverse range of sinus surgeries.
NZIB's recent investment, alongside other investors, will support Chitogel's international market expansion plans and expand its products, allowing the experienced team to continue building from its early success.
EdPotential’s goal is to improve educational achievement by using data to understand performance.
EdPotential provides a web-based SaaS (Software as a Service) product for schools to help teachers inquire into their assessment data, analyse it to identify gaps and strengths, and then act to target solutions that improve student achievement.
It is a data analytics platform that automates the receipt, processing and error correction of data from school management systems, assessment results, and other sources.
Ferronova is a medical device company producing a diagnostic system to aid in the diagnosis and treatment of cancer.
More than 40% of people will be diagnosed with cancer during their lifetime. Successful cancer treatment relies on accurate staging of how far, and where cancer has spread from a primary tumour.
Current diagnostic systems are not able to reliably detect small tumours without invasive surgery. The Ferronova technology addresses this problem in two ways: it can be used as a tracer for MRI scans or in Sentinal Lymph Node Biopsies to identify the spread of cancer and subsequent treatments.
Inhibit Coatings develops and produces antimicrobial surface coatings with activity that lasts the lifetime of the coating. The coatings work to inhibit the growth of potential microbial contamination and outbreaks.
Inhibit's technology is primarily designed for commercial use in facilities with high hygiene and sanitisation requirements – particularly food processing, health care and aged-care facilities.
Inhibit has worked with end-users and suppliers to develop antimicrobial coatings for a range of applications including flooring, walls, textiles and filters. The antimicrobial coatings market is estimated to be US$4.2 billion and growing rapidly.
In 2020, Inhibit secured its first contract with MBIE to develop anti-viral coatings for high-risk areas.
InsituGen has developed a new testing platform for the detection of anabolic drugs in biological samples.The technology can be applied to animals, human athletes and food sources such as nutritional supplements.
The initial focus of the company is directed towards detecting doping in the horseracing industry.
Ligar is developing Molecularly Imprinted Polymers (MIPs) which allow for high-selectivity filtering and extraction, to rebalance compounds in order to improve their quality. The MIPs developed by the company have a wide range of applications, including removing taints from wine, providing decaffeination processes, and allowing cannabinoid extraction, which has drawn global interest.
Originally developed at the Waikato Institute of Technology (WinTec) and the University of Waikato, Ligar is based in Hamilton. In addition to working with several major international companies, Ligar continues to explore opportunities to help grow the Aotearoa economy.
Marama Labs has developed a world-first spectrophotometer, the CloudSpec, that accurately analyses light spectra in cloudy liquids.
Spectroscopy, which uses light to determine the chemical composition of samples, is a standard laboratory technique. Until now it has not been easy to use in liquids that are not clear. The Marama Labs product and technology solves that problem.
Initially, Marama Labs' focus is on the wine industry where the first product is under trial in New Zealand and Australia. It provides real time data on composition of the wine under production that influences taste, colour and mouthfeel. This data will help winemakers better control and improve the quality of their wines.
Over time, Marama Labs aims to expand to other markets where it is critical to understand the underlying chemistry of a cloudy liquid. (e.g. beverages, pharmaceuticals, and wastewater).
Mekonos is disrupting how drugs are delivered to patients, leading the charge with highly-potent cell therapy approaches. This is can be achieved with their custom-developed silicon chips, each holding thousands of individually moving nano-needles, which are used to carry drug cargo that can be injected into the nucleus of cells. This helps to improve uptake and reducing waste.
The initial concept originated from a PhD project at the University of Canterbury. It quickly became clear that the company needed to be in the US, where major innovations in cell therapy are being developed. NZ investment has allowed Mekonos to grow, finding success with major pharmaceutical companies as it moves past the seed stage.
Rekover is developing pharmaceuticals to treat Multiple sclerosis (MS) - a chronic disease that is characterised by increasing loss of motor function and paralysis.
Rekover’s lead asset is a repurposed drug that has shown strong efficacy in animal models and has a well-established and excellent safety record.
The strategy of repurposing an existing drug for a new use means the drug will proceed in the near term to a phase 2 clinical trial, the aim of which is to show the drug benefits MS patients as suggested by the preclinical evaluation conducted at VUW.
XFrame™ is a recoverable and reusable framing system for the next generation of sustainable building construction. XFrame™ replaces the decades-old waste-creating approach of platform timber framing with a structure that enables all adjoining wall layers (things like internal wall linings, insulation and cladding) to be connected in a reversible manner that maintains building integrity. XFrame™ makes recovering and separating building materials so fast and easy that it becomes financial best practice to recover and reuse these materials rather than dispose of them.